Nanjing Anmei Baite Biotechnology Co., Ltd. – Trademark Portfolio
Entity Type: 99
Nanjing Anmei Baite Biotechnology Co., Ltd. holds 9 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 9 filings in this category. Currently, 5 trademarks are registered and 1 is pending. Notable registered marks include ABHAKK, BOKKEE7, NRPRO24, NRPRO7MAX, and NRPRO24MAX. The owner is based in Nanjing City.
Tiexinqiao Street, Yuhuatai District,
No. 48-66 Ningdan Road,
Nanjing City 210012 , CN
Showing of trademarks Trademarks
Trademark Classifications
Nanjing Anmei Baite Biotechnology Co., Ltd.'s trademark portfolio spans 1 Nice Classification class, reflecting the scope of goods and services protected under their brand portfolio.
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Frequently Asked Questions
How many trademarks does Nanjing Anmei Baite Biotechnology Co., Ltd. have?
Nanjing Anmei Baite Biotechnology Co., Ltd. has 9 U.S. trademarks filed with the USPTO. Of these, 5 registered, 1 pending, 3 abandoned.
What trademark classes does Nanjing Anmei Baite Biotechnology Co., Ltd. file in?
Nanjing Anmei Baite Biotechnology Co., Ltd. files trademarks across 1 Nice Classification class. The most active classes are Class 5 (Pharmaceuticals). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.
What are Nanjing Anmei Baite Biotechnology Co., Ltd.'s most well-known trademarks?
Nanjing Anmei Baite Biotechnology Co., Ltd.'s registered trademark portfolio includes well-known marks such as ABHAKK, BOKKEE7, NRPRO24, NRPRO7MAX, and NRPRO24MAX. These are among 5 currently registered trademarks in the portfolio.
What is Nanjing Anmei Baite Biotechnology Co., Ltd.'s trademark registration success rate?
Nanjing Anmei Baite Biotechnology Co., Ltd. has a 63% trademark registration rate, with 5 out of 8 resolved applications resulting in successful registration. Currently, 1 application is pending review.